294.60
0.75 (0.26%)
| Penutupan Terdahulu | 293.85 |
| Buka | 298.39 |
| Jumlah Dagangan | 571,193 |
| Purata Dagangan (3B) | 512,774 |
| Modal Pasaran | 13,288,404,992 |
| Harga / Pendapatan (P/E TTM) | 11.74 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.55 |
| Harga / Jualan (P/S) | 4.91 |
| Harga / Buku (P/B) | 2.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2025 - 4 Aug 2025 |
| Margin Keuntungan | 41.53% |
| Margin Operasi (TTM) | 49.18% |
| EPS Cair (TTM) | 24.65 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 38.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.26% |
| Nisbah Semasa (MRQ) | 5.25 |
| Aliran Tunai Operasi (OCF TTM) | 1.33 B |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 824.72 M |
| Pulangan Atas Aset (ROA TTM) | 12.44% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.23% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | United Therapeutics Corporation | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 0.5 |
| Purata | 1.75 |
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 1.83% |
| % Dimiliki oleh Institusi | 101.57% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 425.00 (HC Wainwright & Co., 44.26%) | Beli |
| Median | 348.00 (18.13%) | |
| Rendah | 314.00 (Wells Fargo, 6.59%) | Pegang |
| 314.00 (B of A Securities, 6.59%) | Pegang | |
| Purata | 350.20 (18.87%) | |
| Jumlah | 2 Beli, 3 Pegang | |
| Harga Purata @ Panggilan | 292.41 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 05 May 2025 | 425.00 (44.26%) | Beli | 298.70 |
| 27 Feb 2025 | 425.00 (44.26%) | Beli | 323.62 | |
| JP Morgan | 01 May 2025 | 350.00 (18.81%) | Beli | 293.85 |
| 21 Apr 2025 | 355.00 (20.50%) | Beli | 284.25 | |
| Morgan Stanley | 01 May 2025 | 348.00 (18.13%) | Pegang | 293.85 |
| Wells Fargo | 25 Apr 2025 | 314.00 (6.59%) | Pegang | 291.38 |
| B of A Securities | 21 Apr 2025 | 314.00 (6.59%) | Pegang | 284.25 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |